Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | PRKCG | P05129 | 2/20 | 0.50 |
| ▸ | PRKCB | P05771 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | PRKCH | P24723 | 2/20 | 0.50 |
| ▸ | PRKCI | P41743 | 2/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729569 | 1.00 | ROCK2 (0.56) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| Hydrochloric Acid SCHEMBL7354044 | 0.99 | ROCK2 (0.55) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL4729428 | 0.96 | ROCK2 (0.56) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL4727732 | 0.96 | ROCK2 (0.56) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL4728375 | 0.96 | ROCK2 (0.56) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL4727753 | 0.95 | MEN1 (0.52) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL4727945 | 0.91 | ROCK2 (0.51) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL7323341 | 0.90 | ROCK2 (0.54) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL7326840 | 0.90 | ROCK2 (0.54) | ROCK2ROCK1MEN1KMT2APRKD3 | |
| SCHEMBL7319670 | 0.90 | ROCK2 (0.54) | ROCK2ROCK1MEN1KMT2APRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0471841-B1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 1995-11-02 | — | — | EP | disclosed |
| US-5340811-A | Bronchodilator agent | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-08-23 | — | — | US | disclosed |
| US-5326870-A | Asthma; bronchodilator agents; respiratory system disorders | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-07-05 | — | — | US | disclosed |
| EP-0525203-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVE OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1993-02-03 | — | — | EP | disclosed |
| EP-0471841-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-02-26 | — | — | EP | disclosed |
| EP-0287696-B1 | ISOQUINOLINE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
| EP-0287696-A1 | Isoquinoline derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ROCK2 2320/4885ROCK1 2248/4885MEN1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.